{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:59:17Z","timestamp":1789840757676,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"China national key research and development program","award":["2022YFC3502000"],"award-info":[{"award-number":["2022YFC3502000"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["SQ2024YFC3500039"],"award-info":[{"award-number":["SQ2024YFC3500039"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Funds of China","doi-asserted-by":"crossref","award":["82174229"],"award-info":[{"award-number":["82174229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai S&T Innovation Plan","award":["17401970900"],"award-info":[{"award-number":["17401970900"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-025-09123-5","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:15:28Z","timestamp":1768562128000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Model-Based Meta-Analysis of IL-17\u00a0A Inhibitors for Moderate-to-Severe Plaque Psoriasis: Establishing Exposure-Response Relationships to Inform Targeted Drug Development"],"prefix":"10.1007","volume":"69","author":[{"given":"Yixiao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoya","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"9123_CR1","doi-asserted-by":"publisher","unstructured":"Boehncke WH, Sch\u00f6n MP, Psoriasis (2015) Lancet 386(9997):983\u2013994. https:\/\/doi.org\/10.1016\/S0140-6736(14)61909-7. (Epub 2015 May 27)","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"9123_CR2","doi-asserted-by":"publisher","unstructured":"Raychaudhuri SK, Maverakis E, Raychaudhuri SP (2014) Diagnosis and classification of psoriasis. Autoimmun Rev. 13(4\u20135):490\u20135 https:\/\/doi.org\/10.1016\/j.autrev.2014.01.008.","DOI":"10.1016\/j.autrev.2014.01.008"},{"issue":"1","key":"9123_CR3","first-page":"97","volume":"93","author":"F Gr\u00e4n","year":"2020","unstructured":"Gr\u00e4n F, Kerstan A, Serfling E, Goebeler M, Muhammad K (2020) Current developments in the immunology of psoriasis. Yale J Biol Med 93(1):97\u2013110","journal-title":"Yale J Biol Med"},{"issue":"5","key":"9123_CR4","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12026-020-09149-1","volume":"68","author":"B Li","year":"2020","unstructured":"Li B, Huang L, Lv P, Li X, Liu G, Chen Y, Wang Z, Qian X, Shen Y, Li Y, Fang W (2020) The role of Th17 cells in psoriasis. Immunol Res 68(5):296\u2013309. https:\/\/doi.org\/10.1007\/s12026-020-09149-1. (Epub 2020 Aug 22)","journal-title":"Immunol Res"},{"issue":"1","key":"9123_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/2589977513666210707114520","volume":"14","author":"A Sharma","year":"2022","unstructured":"Sharma A, Upadhyay DK, Gupta GD, Narang RK, Rai VK (2022) IL-23\/Th17 Axis: A Potential Therapeutic Target of Psoriasis. Curr Drug Res Rev. 14(1):24\u201336. https:\/\/doi.org\/10.2174\/2589977513666210707114520","journal-title":"Curr Drug Res Rev."},{"issue":"1","key":"9123_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaad.2022.01.005IF","volume":"87","author":"C Zhang","year":"2022","unstructured":"Zhang C, Yan K, Diao Q, Guo Q, Jin H, Yang S, Chen X, Lei T, Wu J, Yu H, Zheng M, Gao X, Sinclair R, Zhu Y, Xu Q, Xu J (2022) A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 87(1):95\u2013102. https:\/\/doi.org\/10.1016\/j.jaad.2022.01.005IF","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"9123_CR7","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s13555-022-00880-1","volume":"13","author":"C Jiang","year":"2023","unstructured":"Jiang C, Zhou H, Zhang W, Xia Y, Li B, Ni X, Wang G, Zhang W, Chen B, He Z, Zhang M, Chen R, Jin H, Deng L, Efficacy (2023) Safety and pharmacokinetics of IL-17 monoclonal antibody injection (AK111) in patients with Moderate-to-Severe plaque psoriasis: A Randomized, Double-Blinded, Placebo-Controlled phase Ib multidose escalation clinical study. Dermatol Ther (Heidelb) 13(2):555\u2013567. https:\/\/doi.org\/10.1007\/s13555-022-00880-1. (Epub 2022 Dec 24)","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"9123_CR8","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1007\/s13555-022-00840-9","volume":"12","author":"A Drakos","year":"2022","unstructured":"Drakos A, Vender R (2022) A review of the clinical trial landscape in psoriasis: an update for clinicians. Dermatol Ther (Heidelb) 12(12):2715\u20132730. https:\/\/doi.org\/10.1007\/s13555-022-00840-9. (Epub 2022 Nov 1)","journal-title":"Dermatol Ther (Heidelb)"},{"key":"9123_CR9","unstructured":"U.S. Food & Drug Administration (2015) Clinical Pharmacology and biopharmaceutics review(s)for secukinumab[EB\/OL]. -01-21)[2024-03-08]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/125504Orig1s000TOC.cfm"},{"key":"9123_CR10","unstructured":"U.S. Food & Drug Administration (2016) Clinical Pharmacology and biopharmaceutics review(s)for ixekizumab[EB\/OL]. -06-09)[2024-03-12]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/125521Orig1s000TOC.cfm"},{"key":"9123_CR11","unstructured":"European Medicines Agency, Bimzelx (2021) EPAR-Public assessment report[EB\/OL]. -08-24)[2024-03-12]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bimzelx"},{"key":"9123_CR12","unstructured":"U.S, Food (2015) & Drug Administration. Prescribing information for secukinumab[EB\/OL]. -01-21)[2024-03-08]. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125504"},{"key":"9123_CR13","unstructured":"U.S, Food (2016) & Drug Administration. Prescribing information for ixekizumab[EB\/OL]. -03-22)[2024-03-12]. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process"},{"issue":"2","key":"9123_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.bbrc.2019.07.078","volume":"517","author":"Y Shan","year":"2019","unstructured":"Shan Y, Shi K, Qian X, Chang Z, Yang J, Gao Y, Jin W, Luo Q, Xu Q (2019) Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A. Biochem Biophys Res Commun 517(2):303\u2013309 (Epub 2019 Jul 25)","journal-title":"Biochem Biophys Res Commun"},{"key":"9123_CR15","doi-asserted-by":"publisher","unstructured":"Meng Q, Wang W, Zhang L, Shi H, Liu H, Zheng Q, Xu L (2024) Population Pharmacokinetics of Xeligekimab: An Anti-IL-17A Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. J Clin Pharmacol. Sep 10. https:\/\/doi.org\/10.1002\/jcph.6129. (Epub ahead of print)","DOI":"10.1002\/jcph.6129"},{"issue":"3","key":"9123_CR16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/bjd\/ljae062","volume":"191","author":"L Cai","year":"2024","unstructured":"Cai L, Jiang C, Zhang G, Fang H, Wang J, Li Y, Xu H, Xiao R, Ding Y, Huang K, Zhang C, Zhang L, Chen B, Duan X, Pan W, Han G, Chen R, Liu L, Zhang S, Tao J, Pang X, Yu J, Wang H, Zhao Y, Li C, Kang X, Qin L, Zhu X, Su J, Li S, Yang C, Feng W, Lei T, Jiang S, Fang R, Lin M, Lu Q, Xu C, Wang W, Zhang J (2024) A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 191(3):336\u2013343. https:\/\/doi.org\/10.1093\/bjd\/ljae062","journal-title":"Br J Dermatol."},{"key":"9123_CR17","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","volume":"11","author":"R Adams","year":"2020","unstructured":"Adams R, Maroof A, Baker T, Lawson ADG, Oliver R, Paveley R, Rapecki S, Shaw S, Vajjah P, West S, Griffiths M (2020) Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol 11:1894. https:\/\/doi.org\/10.3389\/fimmu.2020.01894","journal-title":"Front Immunol"},{"issue":"2","key":"9123_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, Paul C, De Cuyper D, Vanvoorden V, Madden C, Cioffi C, Peterson L, Blauvelt A (2021) Bimekizumab versus Secukinumab in plaque psoriasis. N Engl J Med 385(2):142\u2013152. https:\/\/doi.org\/10.1056\/NEJMoa2102383","journal-title":"N Engl J Med"},{"issue":"1","key":"9123_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/cpt.1478","volume":"106","author":"JE Lee","year":"2019","unstructured":"Lee JE, Wang J, Florian J, Wang YM, Kettl D, Marcus K, Woitach A (2019) Effect of body weight on Risk-Benefit and dosing regimen recommendation of Secukinumab for the treatment of moderate to severe plaque psoriasis. Clin Pharmacol Ther 106(1):78\u201380. https:\/\/doi.org\/10.1002\/cpt.1478. (Epub 2019 Jun 12)","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"9123_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/1203475419843118","volume":"23","author":"M Phung","year":"2019","unstructured":"Phung M, Ighani A, Georgakopoulos JR, Vender R, Giroux L, Lansang P, Yeung J (2019) Jul\/Aug) Off-Label High-Dose Secukinumab for the treatment of Moderate-to-Severe psoriasis. J Cutan Med Surg 23(4):391\u2013393","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"9123_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/1203475417721424","volume":"22","author":"J Beecker","year":"2018","unstructured":"Beecker J, Joo J (2018) Treatment of moderate to severe psoriasis with High-Dose (450-mg) secukinumab: case reports of Off-Label use. J Cutan Med Surg 22(1):86\u201388","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"9123_CR22","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjd.20971","volume":"186","author":"M Augustin","year":"2022","unstructured":"Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D (2022) Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol 186(6):942\u2013954. https:\/\/doi.org\/10.1111\/bjd.20971. (Epub 2022 Apr 8)","journal-title":"Br J Dermatol"},{"issue":"2","key":"9123_CR23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.18143","volume":"182","author":"K Reich","year":"2020","unstructured":"Reich K, Puig L, Szepietowski JC, Paul C, Lacour JP, Tsianakas A, Sieder C, Rissler M, Pournara E, Orsenigo R (2020) Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol 182(2):304\u2013315. https:\/\/doi.org\/10.1111\/bjd.18143. (Epub 2019 Sep 8)","journal-title":"Br J Dermatol"},{"issue":"10","key":"9123_CR24","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1080\/17512433.2023.2259300","volume":"16","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xu L, Wang X, Wu L, Cai R, Li L, Zheng Q (2023) Optimization of Secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling. Expert Rev Clin Pharmacol 16(10):999\u20131008","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"11","key":"9123_CR25","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1136\/medethics-2018-104811","volume":"44","author":"P Friesen","year":"2018","unstructured":"Friesen P, Blease C (2018) Placebo effects and Racial and ethnic health disparities: an unjust and underexplored connection. J Med Ethics 44(11):774\u2013781. https:\/\/doi.org\/10.1136\/medethics-2018-104811","journal-title":"J Med Ethics"},{"issue":"5","key":"9123_CR26","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/jdv.14073","volume":"31","author":"JP Lacour","year":"2017","unstructured":"Lacour JP, Paul C, Jazayeri S, Papanastasiou P, Xu C, Nyirady J, Fox T, Papavassilis C (2017) Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatology Venereology: JEADV 31(5):847\u2013856. https:\/\/doi.org\/10.1111\/jdv.14073","journal-title":"J Eur Acad Dermatology Venereology: JEADV"},{"key":"9123_CR27","doi-asserted-by":"publisher","unstructured":"Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E., Papp, K.,Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., Rivas, E., Tsai, T. F., Wasel,N., Tyring, S., Salko, T., Hampele, I., Notter, M., Karpov, A., Helou, S., Papavassilis,C., \u2026 FIXTURE Study Group (2014). Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. New Engl J Med 371(4), 326\u2013338. https:\/\/doi.org\/10.1056\/NEJMoa1314258","DOI":"10.1056\/NEJMoa1314258"},{"key":"9123_CR28","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/ITT.S240891","volume":"10","author":"M Mosca","year":"2021","unstructured":"Mosca M, Hong J, Hadeler E, Hakimi M, Liao W, Bhutani T (2021) The role of IL-17 cytokines in psoriasis. Immunotargets Ther 10:409\u2013418. https:\/\/doi.org\/10.2147\/ITT.S240891","journal-title":"Immunotargets Ther"},{"issue":"1","key":"9123_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","volume":"26","author":"RG Langley","year":"2015","unstructured":"Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C (2015) The 5-point investigator\u2019s global assessment (IGA) scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat 26(1):23\u201331. https:\/\/doi.org\/10.3109\/09546634.2013.865009","journal-title":"J Dermatolog Treat"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09123-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-025-09123-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09123-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:15:35Z","timestamp":1768562135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-025-09123-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9123"],"URL":"https:\/\/doi.org\/10.1007\/s12016-025-09123-5","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}